In CheckMate 227 Part 1A, the nivolumab + ipilimumab arm was associated with a significantly longer OS than platinum-based chemotherapy in metastatic NSCLC patients with PD-L1 TPS ≥1% (HR = 0.79; 97.72% CI [chosen based on hierarchical testing procedure] 0.65–0.96) [9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.